EXELIXIS, INC.

# Exelixis, Inc.

Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes targeted therapies for difficult-to-treat cancers. The company's primary marketed products include CABOMETYX (cabozantinib), a multi-kinase inhibitor approved for advanced renal cell carcinoma and other solid tumors; COMETRIQ (cabozantinib capsules), indicated for progressive medullary thyroid cancer; and COTELLIC (cobimetinib), a MEK inhibitor used in combination regimens for advanced melanoma. Additionally, the company markets MINNEBRO, a mineralocorticoid receptor antagonist approved for hypertension in Japan. These products are derived from or target receptor tyrosine kinases and related pathways including MET, AXL, RET, and VEGF receptors.

The company maintains an active pipeline of investigational programs spanning multiple modalities. Zanzalintinib is a novel oral kinase inhibitor in development, while XL309 targets USP1 as a synthetic lethal agent in BRCA-mutated tumors. Exelixis is also developing antibody-drug conjugates and bispecific antibodies, including XB010, XB628, and XB371, representing an expansion beyond small-molecule therapeutics. The company has established research collaborations and licensing agreements with multiple pharmaceutical and biotechnology firms including Ipsen, Takeda, Roche, and Daiichi Sankyo.

Headquartered in Alameda, California, Exelixis operates with approximately 1,077 full-time employees and generates revenue primarily from its marketed oncology and cardiovascular products distributed in the United States and select international markets.